Cargando…

Reimbursement measures in European countries – findings of a bibliometric literature review

Detalles Bibliográficos
Autores principales:	Vogler, Sabine, Zimmermann, Nina, de Labry, Antonio Olry, Espin, Jaime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603622/ http://dx.doi.org/10.1186/2052-3211-8-S1-P21

Ejemplares similares

Description of day case costs and tariffs of cataract surgery from a sample of nine European countries
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2022)

Policy options to deal with high-cost medicines – survey with European policy-makers
por: Zimmermann, Nina, et al.
Publicado: (2015)

Prices of oncology medicines in European countries, Australia and New Zealand
por: Vogler, Sabine, et al.
Publicado: (2015)

Development of the European Healthcare and Social Cost Database (EU HCSCD) for use in economic evaluation of healthcare programs
por: Espín, Jaime, et al.
Publicado: (2022)

Design of value-added tax on medicines in 41 European countries
por: Vogler, S, et al.
Publicado: (2022)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
por: Lipińska, Aneta, et al.
Publicado: (2015)

The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?
por: Vogler, Sabine, et al.
Publicado: (2015)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

Pharmaceutical policies in European countries in response to the global financial crisis
por: Vogler, Sabine, et al.
Publicado: (2011)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Diagnosis-related group-based reimbursement is unrealistic for ICUs
por: Mclaughlin, A, et al.
Publicado: (2009)

Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015)

Correction to: A general framework for classifying costing methods for economic evaluation of health care
por: Špacírová, Zuzana, et al.
Publicado: (2021)

A general framework for classifying costing methods for economic evaluation of health care
por: Špacírová, Zuzana, et al.
Publicado: (2020)

Retrospective financial analysis of medicines reimbursement services in community pharmacy
por: Chitan, Elena
Publicado: (2015)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2016)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Microcosting study of ICU costs in three European countries
por: Tan, SS, et al.
Publicado: (2008)

“Ready for the future?” – Status of national and cross-country horizon scanning systems for medicines in European countries
por: Vogler, Sabine
Publicado: (2022)

How is intensive care reimbursed? A review of eight European countries
por: Bittner, Martin-Immanuel, et al.
Publicado: (2013)

Pharmaceutical distribution remuneration in Europe
por: Vogler, Sabine, et al.
Publicado: (2015)

The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
por: Mordi, Dumebi O, et al.
Publicado: (2015)

Differences in paediatric rheumatology services in European countries – results of an international survey
por: Vesely, R
Publicado: (2008)

Prohibit WP2 – systematic review of national guidelines in European countries
por: Martin, M, et al.
Publicado: (2011)

Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
por: Vogler, Sabine, et al.
Publicado: (2019)

Reimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment
por: Kazakov, Rossen M, et al.
Publicado: (2015)

Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
por: Noordman, Janneke, et al.
Publicado: (2010)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Incidence, costs and outcomes of avoidable hospitalizations in a southern European country: is there room for improvement?
por: Soares-dos-Reis, R, et al.
Publicado: (2012)

PReS-FINAL-2209: MEFV gene mutations in central and south-eastern European countries
por: Perko, D, et al.
Publicado: (2013)

Impact of Generic Price Linkage System and Reference Price System on prices of pharmaceuticals – comparison of Austria and Finland
por: Martikainen, Jaana E, et al.
Publicado: (2015)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Findings of the literature review on mobility, infectious diseases and malaria
por: Whittaker, Maxine, et al.
Publicado: (2012)

Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study
por: Ágh, Tamás, et al.
Publicado: (2022)

Findings of the literature review on larviciding in elimination environments in Asia Pacific
por: Whittaker, Maxine, et al.
Publicado: (2012)

Findings of the literature review on larviciding in elimination environments in Asia Pacific
por: Whittaker, Maxine, et al.
Publicado: (2012)

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k6jdjbhub6i6rprjfmpdcaq6cm